---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-312390"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2026-07-22T20:05:15+00:00"
generated_at: "2026-07-22T20:06:17.867725+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# NewAmsterdam COO Douglas Kling resigns to become CEO of another biotech; transition expected

## Summary
- Douglas Kling notified resignation as COO effective August 14, 2026.
- Kling will become CEO of another clinical-stage biotech company.
- Company expects separation agreement and advisor agreement for transition services.
- Advisor role will focus on PREVAIL clinical trial of obicetrapib and other programs.
- No replacement for COO announced.

## SEC filing metadata
- accession: 0001193125-26-312390
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2026-07-22T20:05:15+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000119312526312390/0001193125-26-312390-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000119312526312390/nams-20260716.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-312390
- JSON: https://secwatch.observer/filing/0001193125-26-312390.json
- Plain text: https://secwatch.observer/filing/0001193125-26-312390.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.